Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
复制标题
DOI：
10.12788/acp.0048
复制
发表时间：
2022-03
影响因子：
1.3
通讯作者：
Mathew, Sanjay J.
中科院分区：
文献类型：
--
作者：
Kritzer, Michael D.;Mischel, Nicholas A.;Young, Jonathan R.;Lai, Christopher S.;Masand, Prakash S.;Szabo, Steven T.;Mathew, Sanjay J.
情绪障碍是发病的主要原因。许多患者患有难治性抑郁症（TRD），自杀率正在上升。需要更快、更有效的抗抑郁药物。四十年的研究已经将氯胺酮的使用从麻醉剂转变为重度抑郁症（MDD）的门诊治疗。氯胺酮是一种N-甲基-d-天冬氨酸（NMDA）受体拮抗剂，已被证明可通过直接靶向谷氨酸系统迅速改善情绪症状和自杀意念。我们使用PubMed数据库识别截至2020年9月1日发表的相关文章。我们专注于荟萃分析、随机对照试验和原始观察性研究。我们纳入了抑郁症、MDD、TRD、双相情感障碍、焦虑、创伤后应激障碍（PTSD）、自杀、氯胺酮和艾司氯胺酮的相关研究。外消旋氯胺酮和艾司氯胺酮均已被证明可快速治疗抑郁症和自杀倾向。有证据表明，氯胺酮可以帮助焦虑和创伤后应激障碍;然而，需要更多的研究。鼻内艾司氯胺酮已被FDA批准用于治疗抑郁症。这篇叙述性综述描述了氯胺酮治疗情绪障碍和自杀倾向的演变。我们提供的证据支持使用艾司氯胺酮的最新发展以及该领域尚未解决的问题，如剂量和安全性。
Mood disorders are a leading cause of morbidity. Many patients experience treatment-resistant depression (TRD), and suicide rates are rising. Faster-acting and more effective antidepressant medications are needed. Four decades of research has transformed the use of ketamine from an anesthetic to an outpatient treatment for major depressive disorder (MDD). Ketamine is a N-methyl-d-aspartate (NMDA) receptor antagonist and has been shown to rapidly improve mood symptoms and suicidal ideation by targeting the glutamate system directly. We used the PubMed database to identify relevant articles published until September 1, 2020. We focused on meta-analyses, randomized controlled trials, and original observational studies. We included relevant studies for depression, MDD, TRD, bipolar disorder, anxiety, posttraumatic stress disorder (PTSD), suicide, ketamine, and esketamine. Both racemic ketamine and esketamine have been shown to rapidly treat depression and suicidality. There is evidence that ketamine can be helpful for anxiety and PTSD; however, more research is needed. Intranasal esketamine has been FDA approved to treat depression. This narrative review describes the evolution of ketamine to treat mood disorders and suicidality. We provide the evidence supporting recent developments using esketamine as well as unresolved issues in the field, such as dosing and safety.
登录
查看更多内容
影响因子：
11
作者：
Fava M;Freeman MP;Flynn M;Judge H;Hoeppner BB;Cusin C;Ionescu DF;Mathew SJ;Chang LC;Iosifescu DV;Murrough J;Debattista C;Schatzberg AF;Trivedi MH;Jha MK;Sanacora G;Wilkinson ST;Papakostas GI
通讯作者：
Papakostas GI
影响因子：
4.1
作者：
Glue, Paul;Medlicott, Natalie J.;McNaughton, Neil
通讯作者：
McNaughton, Neil
影响因子：
4.8
作者：
Fedgchin, Maggie;Trivedi, Madhukar;Singh, Jaskaran B.
通讯作者：
Singh, Jaskaran B.
影响因子：
4.1
作者：
Diamond, Peter R.;Farmery, Andrew D.;McShane, Rupert
通讯作者：
McShane, Rupert
影响因子：
10.6
作者：
Berman, RM;Cappiello, A;Krystal, JH
通讯作者：
Krystal, JH